ONC201 may inhibit cancer stem cell self-renewals by altering their gene expression Pre-treatment gene expression of cancer stem cells may help predict response to ONC201 ONC201 may inhibit cancer stem cell self-renewals by altering their gene expression, according to a study published August 2, 2017 in the open-access journal PLOS ONE by Varun Vijay Prabhu from
The Musella Foundation recently awarded Oncoceutics a $25,000 research grant for a project titled “Clinical Evaluation of DRD5 as a Predictive Biomarker of Response to the selective DRD2 antagonist ONC201.” This will fund Oncoceutics’ work evaluating the impact of dopamine receptor expression on the responsiveness of patient tumors to ONC201, with a focus on glioblastoma
The recently published results from a clinical trial of ONC201 in patients with recurrent glioblastoma were featured in a recent article from Bioscience Technology. The full article can be read here.
Cambridge Healthtech Institute recently spoke with Dr. Michel Bouvier of Université de Montréal about his insights on GPCRs and where the field is headed in coming years. The full interview can be found here.
Business Development